■ 学術雑誌
|
原著
|
|
1.
|
中島孝治, 柴田伸弘, 田原良博, 細川歩：
大腸癌化学療法における血管新生阻害薬の位置づけ (特集 大腸癌化学療法).
消化器・肝臓内科
5
(1)
：24
-32
, 2019
|
|
2.
|
Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, Yasui H, Hashida T, Kaihara S, Inokuma T, Tsuji A：
Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
Asia-Pacific journal of clinical oncology
15
(1)
：63
-68
, 2019
|
|
3.
|
Kikawa Y, Hatachi Y, Rumpold G, Tokiwa M, Takebe S, Ogata T, Satake H, Kato H, Tsuji A, Yasui H, Holzner B：
Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study.
Breast cancer
26
(2)
：255
-259
, 2019
|
|
4.
|
Satake H, Sagawa T, Fujikawa K, Hatachi Y, Yasui H, Kotaka M, Kato T, Tsuji A：
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Cancer chemotherapy and pharmacology
82
(5)
：839
-845
, 2018
|
|
5.
|
Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K：
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
Cancer medicine
7
(9)
：4217
-4227
, 2018
|
|
6.
|
Ogata T, Kikawa Y, Ogata M, Satake H, Hatachi Y, Yasui H.：
Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports.
Case reports in oncology
11
(3)
：699
-704
, 2018
|
|
7.
|
Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E：
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Clinical colorectal cancer
17
(4)
：e687
-e697
, 2018
|
|
8.
|
Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).：
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
European Journal of Cancer
105
：41
-49
, 2018
|
|
9.
|
Satake H, Tsuji A, Nakamura M, Ogawa M, Kotake T, Hatachi Y, Yasui H, Takagane A, Okita Y, Nakamura K, Onikubo T, Takeuchi M, Fujii M：
Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
International journal of clinical oncology
23
(3)
：490
-496
, 2018
|
|
10.
|
Yabushita T, Satake H, Maruoka H, Morita M, Katoh D, Shimomura Y, Yoshioka S, Morimoto T, Ishikawa T：
Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
Leukemia & lymphoma
59
(9)
：2144
-2151
, 2018
|
|
11.
|
Ogata T, Satake H, Ogata M, Hatachi Y, Maruoka H, Yamashita D, Hashida H, Hamada M, Yasui H.：
Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study.
Oncotarget
10
(10)
：1070
-1084
, 2019
|
|
12.
|
Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T：
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
Oncotarget
9
(27)
：18811
-18820
, 2018
|
|
13.
|
Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T：
Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
Oncotarget
9
(52)
：30023
, 2018
|
|
14.
|
Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M, Yasui H：
Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study.
Oncotarget
9
(77)
：34520
-34527
, 2018
|
|
15.
|
Sunakawa Y, Satake H, Ichikawa W：
Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors.
World journal of gastrointestinal oncology
10
(12)
：528
-531
, 2018
|
|
その他
|
|
1.
|
Uchida T, Yamaguchi H, Nagamine K, Yonekawa T, Nakamura E, Nakamura E, Shibata N, Kawano F, Asada Y, Nakazato M：
Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer.
Endocrinology, diabetes & metabolism case reports
：Online ahead of print
, 2019
|
|
2.
|
Komatsu, Y; Kato, T; Kagawa, Y; Yoshino, T; Kuboki, Y; Gamoh, M; Yasui,
H; Yamazaki, K; Satake, H; Goto, M; Tanioka, H; Oki, E; Kotaka, M;
Makiyama, A; Denda, T; Soeda, J; Shibuya, K; Iwata, M; Oba, K;
Yamaguchi, K：
Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
Journal of clinical oncology
37
(4S)
：624
, 2019
|
|
3.
|
Kotaka, M; Satake, H; Oba, K; Kagawa, Y; Yasui, H; Nakamura, M;
Watanabe, T; Matsumoto, T; Kii, T; Terazawa, T; Makiyama, A; Takano, N;
Yokota, M; Okita, Y; Matoba, K; Hasegawa, H; Tsuji, A; Nagata, N;
Sakamoto, J; Kato, T：
Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BITS study).
Journal of clinical oncology
37
(4S)
：647
, 2019
|
|
■ 学会発表
|
国際学会及び海外の学会
|
|
1.
|
◎Satake H, Suzuki T, Imamura CK, Sukawa Y, Masuishi T, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T：
Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer.
AACR,
アトランタ, USA,
2019/03
|
|
2.
|
◎Komatsu Y, Kato T, Kagawa Y, Yoshino T, Kuboki Y, Gamoh M, Yasui H, Yamazaki K, Satake H, Goto M, Tanioka H, Oki E, Kotaka M, Makiyama A, Denda T, Soeda J, Shibuya K, Iwata M, Oba K, Yamaguchi K：
Phase I/II study of panitumumab combined with trifluridine/tipiracil in patients with previously treated RAS wild-type metastatic colorectal cancer: Final results of APOLLON study.
ASCO GI,
SF, USA,
2019/01
|
|
3.
|
◎Hamada M, Uetsuki T, Sumiyama F, Kobayashi T, Matsushima H, Hisanori, Satake H：
Implication of the CRM value of vivo MRI for preoperative chemoradiotherapy of the middle to low rectal cancer.
European Colorectal Congress 2019,
スイス,
2018/12
|
|
その他
|
|
1.
|
◎植月友彦、吉田明史、小林壽範、松島英之、三木博和、佐竹悠良、三城弥範、向出裕美、道浦 拓、井上健太郎、濱田 円：
当科で切除した小腸腫瘍症例の検討.
第89回大腸癌研究会,
新潟,
2018/07
|
|
